Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

Roshini Claire Anthony, one year ago

Patients with pancreatic adenocarcinoma (PDAC) given adjuvant chemotherapy (ACT) appeared to have better overall survival (OS) than those given adjuvant chemoradiation therapy (ACRT), according to new research.

TNFi effectiveness: nonradiographic axial spondyloarthritis vs ankylosing spondylitis

4 months ago

Subjective disease activity is higher in patients with nonradiographic axial spondyloarthritis (nr-axSpA) at start of tumour necrosis factor inhibitor (TNFi) treatment, but outcomes are similar to patients with ankylosing spondylitis (AS) after adjusting for confounders, according to a nationwide cohort study.

In addition, HLA-B27 positivity is associated with better outcomes regardless of axSpA subdiagnosis.

Researchers conducted an observational cohort study based on data from the nationwide DANBIO registry to compare baseline disease activity and treatment effectiveness in biologic-naïve patients with nr-axSpA and AS who started TNFi treatment, as well as to analyse the role of potential confounders (sex/age/start yr/HLA-B27/disease duration/TNFi-type/smoking/baseline disease activity).

Kaplan-Meier plots, Cox and logistic regression analyses were used to assess the effect of diagnosis (nr-axSpA vs AS) and potential confounders on TNFi adherence and response (eg, Bath Ankylosing Spondylitis Activity Index [BASDAI] 50 percent/20 mm).

At TNFi initiation, nr-axSpA patients had higher visual analogue scale scores, compared with AS patients, for pain (median 72 vs 65 mm), global (76 vs 68 mm), fatigue (74 vs 67 mm) and BASDAI (64 vs 59; p<0.01 for all). Patients with nr-axSpA, however, had lower C-reactive protein (7 vs 11 mg) and BAS Metrology Index (20 vs 40; p<0.01 for all).

Median treatment adherence was poorer in nr-axSpA than in AS patients (1.59 years; 95 percent CI, 1.15 to 2.02 vs 3.67 years; 2.86 to 4.49; p<0.0001) in univariate analysis, but not in confounder-adjusted analysis (p>0.05). Both nr-axSpA and AS groups had similar response rates (p>0.05).

HLA-B27 negativity correlated with poorer treatment adherence (HLA-B27 negative/positive, nr-axSpA: hazard ratio [HR], 1.74; 1.29 to 2.36; AS: HR, 2.04; 1.53 to 2.71; p<0.0001 for both) and lower response rates (nr-axSpA: 30 vs 55 percent; AS: 29 vs 54 percent; both p<0.05).

A total of 1,250 TNFi-naïve patients with axSpA were included in the study. Patients with nr-axSpA were more frequently women (50/27 percent) and HLA-B27–negative (25 percent), compared to AS (17 percent; p<0.01).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

Roshini Claire Anthony, one year ago

Patients with pancreatic adenocarcinoma (PDAC) given adjuvant chemotherapy (ACT) appeared to have better overall survival (OS) than those given adjuvant chemoradiation therapy (ACRT), according to new research.